Australia's most trusted
source of pharma news
Wednesday, 10 December 2025
Posted 8 December 2025 PM
Pfizer’s haemophilia prophylactic Hympavzi has produced impressive results in a phase 3 trial involving patients with inhibitors to factor replacement therapies.
An anti-TFPI antibody, Hympavzi is currently under MSAC review for reimbursement under the National Blood Agreement as a treatment for patients without inhibitors.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.